Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$12.38
-4.8%
$13.20
$6.42
$16.33
$2.73B1.58773,765 shs479,532 shs
Indivior PLC stock logo
INDV
Indivior
$17.09
+0.7%
$19.54
$14.38
$26.50
$2.34B0.63103,877 shs76,147 shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$47.99
+1.9%
$46.09
$5.65
$65.60
$2.44B3.87905,828 shs903,847 shs
Verano Holdings Corp. stock logo
VRNOF
Verano
$4.87
-6.3%
$5.32
$2.53
$7.08
$1.79B1.49672,568 shs240,037 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
-4.77%-4.81%+0.08%-7.34%+75.60%
Indivior PLC stock logo
INDV
Indivior
+0.71%-4.36%-7.72%+2.58%+1,708,999,900.00%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+1.89%-4.00%-1.44%+381.83%+259.21%
Verano Holdings Corp. stock logo
VRNOF
Verano
-6.35%-1.02%-2.01%-17.32%+72.61%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
3.7766 of 5 stars
3.54.00.00.02.30.83.1
Indivior PLC stock logo
INDV
Indivior
3.3864 of 5 stars
3.54.00.00.00.01.71.9
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.4293 of 5 stars
4.53.00.00.02.53.30.0
Verano Holdings Corp. stock logo
VRNOF
Verano
1.8975 of 5 stars
3.53.00.00.01.90.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
3.00
Buy$39.88222.09% Upside
Indivior PLC stock logo
INDV
Indivior
3.00
Buy$36.00110.65% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.00
Buy$69.5044.82% Upside
Verano Holdings Corp. stock logo
VRNOF
Verano
3.00
Buy$7.0043.74% Upside

Current Analyst Ratings

Latest GTBIF, VRNOF, INDV, and JANX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $63.00
5/10/2024
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.00 ➝ $16.00
5/9/2024
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.50 ➝ $17.00
5/9/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$100.00
5/8/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$53.00 ➝ $74.00
5/8/2024
Verano Holdings Corp. stock logo
VRNOF
Verano
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
4/16/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$70.00
4/3/2024
Indivior PLC stock logo
INDV
Indivior
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
3/21/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
3/20/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$100.00
3/13/2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $48.00
(Data available from 5/21/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$1.05B2.47$0.62 per share19.95$8.10 per share1.53
Indivior PLC stock logo
INDV
Indivior
$1.09B2.16$1.83 per share9.32$0.37 per share46.19
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$8.08M307.96N/AN/A$7.46 per share6.43
Verano Holdings Corp. stock logo
VRNOF
Verano
$938.45M1.79$0.25 per share19.18$3.61 per share1.35

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$36.27M$0.2451.5934.39N/A5.38%3.39%2.32%N/A
Indivior PLC stock logo
INDV
Indivior
$2M$0.011,709.006.60N/A0.44%842.72%12.42%7/25/2024 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$58.29M-$1.22N/AN/AN/A-762.92%-13.49%-12.37%8/13/2024 (Estimated)
Verano Holdings Corp. stock logo
VRNOF
Verano
-$117.35M-$0.32N/AN/AN/A-12.11%-4.28%-2.35%N/A

Latest GTBIF, VRNOF, INDV, and JANX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$0.06$0.13+$0.07$0.13$271.03 million$275.81 million    
5/8/2024Q1 2024
Verano Holdings Corp. stock logo
VRNOF
Verano
-$0.08-$0.01+$0.07-$0.01$215.71 million$221.31 million
5/7/2024Q1 2024
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.35-$0.30+$0.05-$0.30$0.98 million$1.25 million
4/25/2024Q1 2024
Indivior PLC stock logo
INDV
Indivior
$0.38$0.37-$0.01$0.40$300.00 million$284.00 million
3/15/2024Q4 2023
Verano Holdings Corp. stock logo
VRNOF
Verano
-$0.05-$0.07-$0.02$0.08$233.22 million$237.19 million
3/8/2024Q4 2023
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.37-$0.25+$0.12-$0.25$0.98 million$2.46 million
2/28/2024Q4 2023
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
$0.05$0.01-$0.04$0.01$270.07 million$278.23 million    
2/22/202412/31/2023
Indivior PLC stock logo
INDV
Indivior
$0.28$0.43+$0.15$0.48$260.00 million$293.00 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
Verano Holdings Corp. stock logo
VRNOF
Verano
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
N/A
2.40
1.72
Indivior PLC stock logo
INDV
Indivior
23.50
0.92
0.74
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
62.09
62.09
Verano Holdings Corp. stock logo
VRNOF
Verano
0.39
1.01
0.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
0.09%
Indivior PLC stock logo
INDV
Indivior
60.33%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
Verano Holdings Corp. stock logo
VRNOF
Verano
8.98%

Insider Ownership

CompanyInsider Ownership
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
11.90%
Indivior PLC stock logo
INDV
Indivior
N/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
35.40%
Verano Holdings Corp. stock logo
VRNOF
Verano
18.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Green Thumb Industries Inc. stock logo
GTBIF
Green Thumb Industries
4,600210.36 million185.33 millionNot Optionable
Indivior PLC stock logo
INDV
Indivior
1,164137.88 millionN/ANot Optionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
6451.85 million33.50 millionOptionable
Verano Holdings Corp. stock logo
VRNOF
Verano
3,900344.16 million279.12 millionNot Optionable

GTBIF, VRNOF, INDV, and JANX Headlines

Recent News About These Companies

Marijuana Stocks To Buy In Today's Cannabis Market
Top Marijuana Stocks For Cannabis Investing In May
Verano Q1 Revenue Falls

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Green Thumb Industries logo

Green Thumb Industries

OTCMKTS:GTBIF
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
Indivior logo

Indivior

NASDAQ:INDV
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Janux Therapeutics logo

Janux Therapeutics

NASDAQ:JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Verano logo

Verano

OTCMKTS:VRNOF
Verano Holdings Corp. operates as a vertically integrated multi-state cannabis operator in the United States. The company engages in the cultivation, processing, wholesale, and retail distribution of cannabis in Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia. It offers cannabis products under the Encore, Avexia, MUV, Savvy, BITS, and Verano brands for medical and adult-use markets. The company is headquartered in Chicago, Illinois.